Skip to Main Content

Last year, Arrakis Therapeutics announced early but important progress toward a drug-development goal long thought to be a biotech fantasy: the creation of oral medicines that can target RNA, the messenger-like molecules that turn genetic instructions into proteins.

On Wednesday, the Waltham, Mass.-based startup checked another box on its list of milestones: signing on its first strategic partner, the Swiss pharma giant Roche, which will pay $190 million upfront to license Arrakis’ technology. The two companies will work together to develop a new class of pills with potential to block the RNA machinery that makes disease-causing proteins.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED